EGFR and cutaneous squamous cell carcinoma: In A431 cells, representing a model of cutaneous squamous cell carcinoma, these bispecific antibodies (such as the ATTACK format) have shown strong binding affinity and effectively inhibited downstream EGFR signaling pathways and cell proliferation (124).In the A431 xenograft model, significant inhibition of tumor growth was achieved by the EGFR/CD3 bispecific antibody through activation of T cell-mediated Tumor Cells killing (125).